Wrobe D, Henseler M, Huettler S, Pascual Pascual S I, Chabas A, Sandhoff K
Kekulé-Institut für Organische Chemie und Biochemie, Universität Bonn, Germany.
J Inherit Metab Dis. 2000 Feb;23(1):63-76. doi: 10.1023/a:1005603014401.
The lysosomal degradation of sphingolipids with short oligosaccharide chains depends on small glycosylated non-enzymatic sphingolipid activator proteins (SAPs, saposins). Four of the five known SAPs, SAP-A, -B, -C and -D, are derived by proteolytic processing from a common precursor protein (SAP-precursor) that is encoded by a gene on chromosome 10 consisting of 15 exons and 14 introns. SAP-B is a non-specific glycolipid binding protein that stimulates in vitro the hydrolysis of about 20 glycolipids by different enzymes. In vivo SAP-B stimulates in particular the degradation of sulphatides by arylsulphatase A. So far, four different point mutations have been identified on the SAP-B domain of the SAP-precursor gene. The mutations result in a loss of mature SAP-B, causing the lysosomal accumulation of sulphatides and other sphingolipids, resulting in variant forms of metachromatic leukodystrophy (MLD). Here we report on a patient with SAP-B deficiency that is caused by a new homoallelic point mutation that has been identified by mRNA and DNA analysis. A 643A > C transversion results in the exchange of asparagine 215 to histidine and eliminates the single glycosylation site of SAP-B. Metabolic labelling experiments showed that the mutation had no effect on the intracellular transport of the encoded precursor to the acidic compartments and its maturation in the patient's cells. All four SAPs (SAP-A to SAP-D) were detectable by immunochemical methods. SAP-B in the patient's cells was found to be slightly less stable than the protein in normal cells and corresponded in size to the deglycosylated form of the wild-type SAP-B. Feeding studies with non-glycosylated SAP-precursor, generating non-glycosylated SAP-B, showed that the loss of the carbohydrate chain reduced the intracellular activity of the protein significantly. The additional structural change of the patient's SAP-B, caused by the change of amino acid 215 from asparagine to histidine, presumably resulted in an almost completely inactive protein.
具有短寡糖链的鞘脂的溶酶体降解依赖于小的糖基化非酶鞘脂激活蛋白(SAPs,鞘脂激活蛋白)。已知的五种SAPs中的四种,即SAP-A、-B、-C和-D,是通过蛋白水解加工从一个共同的前体蛋白(SAP前体)衍生而来,该前体蛋白由位于10号染色体上的一个基因编码,该基因由15个外显子和14个内含子组成。SAP-B是一种非特异性糖脂结合蛋白,在体外可刺激约20种糖脂被不同酶水解。在体内,SAP-B尤其能刺激芳基硫酸酯酶A对硫脂的降解。到目前为止,在SAP前体基因的SAP-B结构域上已鉴定出四种不同的点突变。这些突变导致成熟的SAP-B缺失,引起硫脂和其他鞘脂在溶酶体中蓄积,导致异染性脑白质营养不良(MLD)的不同变异形式。在此,我们报告一名因新的纯合子点突变导致SAP-B缺乏的患者,该突变通过mRNA和DNA分析得以鉴定。一个643A>C的颠换导致天冬酰胺215被组氨酸取代,并消除了SAP-B的单个糖基化位点。代谢标记实验表明,该突变对编码的前体向酸性区室的细胞内转运及其在患者细胞中的成熟没有影响。通过免疫化学方法可检测到所有四种SAPs(SAP-A至SAP-D)。发现患者细胞中的SAP-B比正常细胞中的蛋白稳定性略低,其大小与野生型SAP-B的去糖基化形式一致。用非糖基化的SAP前体进行喂养研究,产生非糖基化的SAP-B,结果表明碳水化合物链的缺失显著降低了该蛋白的细胞内活性。患者的SAP-B由于氨基酸215从天冬酰胺变为组氨酸而导致的额外结构变化,可能导致该蛋白几乎完全失活。